Human microvascular endothelial cells resist Shiga toxins by IFN- treatment Free

Abstract

Shiga toxins (Stxs) produced by enterohaemorrhagic or damage human endothelial cells predominantly in cooperation with pro-inflammatory cytokines, such as TNF-. However, in this study, IFN- pre-treatment resulted in human lung microvascular endothelial cells becoming over 10 000-fold less sensitive to Stxs. In contrast, in their basal condition, they were extremely sensitive to Stxs. Interestingly, TNF- addition to IFN- reverted the Stx-resistant phenotype, which corresponded with its well-established enhancing effect on Stx toxicity. Toxin binding to the cell was barely affected by IFN-. Also, the toxin uptake in the Stx-resistant phenotype was more than 100-fold greater than that of normal cells, when compared at Stx concentrations resulting in equivalent degrees of cell damage. Protein synthesis was inhibited by nearly 90 % in the Stx-resistant phenotype after 24 h toxin exposure. This indicated that the intracellular toxin was active as an -glycosidase, while cells were still over 60 % viable, suggesting a possible unknown cytotoxic function of Stx. In conclusion, this study shows a unique effect of IFN- in the suppression of the toxicity of Stxs in a human microvascular endothelial cell model and the involvement of a novel mechanism in this suppression.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.26142-0
2003-09-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/micro/149/9/mic1492609.html?itemId=/content/journal/micro/10.1099/mic.0.26142-0&mimeType=html&fmt=ahah

References

  1. Arab S., Lingwood C. A. 1998; Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic. J Cell Physiol 177:646–660
    [Google Scholar]
  2. Banatvala N., Griffin P. M., Greene K. D., Barrett T. J., Bibb W. F., Green J. H., Wells J. G. Hemolytic Uremic Syndrome Study Collaborators 2001; The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 183:1063–1070
    [Google Scholar]
  3. Bhimma R., Rollins N. C., Coovadia H. M., Adhikari M. 1997; Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal. Pediatr Nephrol 11:560–564
    [Google Scholar]
  4. Decludt B., Bouvet P., Mariani-Kurkdjian P., Grimont F., Grimont P. A., Hubert B., Loirat C. 2000; Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Societe de Nephrologie Pediatrique. Epidemiol Infect 124:215–220
    [Google Scholar]
  5. Eisenhauer P. B., Chaturvedi P., Fine R. E., Ritchie A. J., Pober J. S., Cleary T. G., Newburg D. S. 2001; Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun 69:1889–1894
    [Google Scholar]
  6. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. 1988; Site of action of a Vero toxin (VT2) from Escherichia coli O157 : H7 and of Shiga toxin on eukaryotic ribosomes. RNA N -glycosidase activity of the toxins. Eur J Biochem 171:45–50
    [Google Scholar]
  7. Garred O., van Deurs B., Sandvig K. 1995; Furin-induced cleavage and activation of Shiga toxin. J Biol Chem 270:10817–10821
    [Google Scholar]
  8. Gianviti A., Rosmini F., Caprioli A., Corona R., Matteucci M. C., Principato F., Luzzi I., Rizzoni G. 1994; Haemolytic-uraemic syndrome in childhood: surveillance and case-control studies in Italy. Italian HUS Study Group. Pediatr Nephrol 8:705–709
    [Google Scholar]
  9. Guardabasso V., Munson P. J., Rodband D. 1988; A versatile method for simultaneous analysis of families of curves. FASEB J 2:209–215
    [Google Scholar]
  10. Karmali M. A., Petric M., Lim C., Fleming P. C., Arbus G. S., Lior H. 1985; The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli . J Infect Dis 151:775–782
    [Google Scholar]
  11. Keusch G. T., Acheson D. W., Aaldering L., Erban J., Jacewicz M. S. 1996; Comparison of the effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. J Infect Dis 173:1164–1170
    [Google Scholar]
  12. Kondo F., Kobayashi S., Matsumoto K., Yamada S., Saito M., Suzuki Y., Ishikawa N., Nakanishi T., Shimizu A. 1997; Analysis of Vero toxins 1 and 2 by high-performance liquid chromatography/electrospray ionization mass spectrometry. J Mass Spectrom 32:1140–1142
    [Google Scholar]
  13. Laurence J., Mitra D. 1997; Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome. Semin Hematol 34:98–105
    [Google Scholar]
  14. Molostvov G., Morris A., Rose P., Basu S. 2001; Interaction of cytokines and growth factor in the regulation of verotoxin-induced apoptosis in cultured human endothelial cells. Br J Haematol 113:891–897
    [Google Scholar]
  15. Ohmi K., Kiyokawa N., Takeda T., Fujimoto J. 1998; Human microvascular endothelial cells are strongly sensitive to Shiga toxins. Biochem Biophys Res Commun 251:137–141
    [Google Scholar]
  16. Pijpers A. H., van Setten P. A., van den Heuvel L. P., Assmann K. J., Dijkman H. B., Pennings A. H., Monnens L. A., van Hinsbergh V. W. 2001; Verocytotoxin-induced apoptosis of human microvascular endothelial cells. J Am Soc Nephrol 12:767–778
    [Google Scholar]
  17. Siegler R. L., Pysher T. J., Tesh V. L., Taylor F. B. Jr 2001; Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol 12:1458–1467
    [Google Scholar]
  18. Taylor F. B. Jr, Tesh V. L., DeBault L., Li A., Chang A. C., Kosanke S. D., Pysher T. J., Siegler R. L. 1999; Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 154:1285–1299
    [Google Scholar]
  19. van de Kar N. C., Monnens L. A., Karmali M. A., van Hinsbergh V. W. 1992; Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80:2755–2764
    [Google Scholar]
  20. Wanders R. J. A., Romeyn G. J., Schutgens R. B. H., Tager J. M. 1989; l-Pipecolate oxidase: a distinct peroxisomal enzyme in man. Biochem Biophys Res Commun 164:550–555
    [Google Scholar]
  21. Wang J. H., Redmond H. P., Watson R. W., Condron C., Bouchier-Hayes D. 1999; Involvement of tyrosine protein kinase in IFN-gamma-induced human endothelial cell apoptosis. Shock 11:311–318
    [Google Scholar]
  22. Wills R. J. 1990; Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19:390–399
    [Google Scholar]
  23. Yoshida T., Fukada M., Koide N., Ikeda H., Sugiyama T., Kato Y., Ishikawa N., Yokochi T. 1999; Primary cultures of human endothelial cells are susceptible to low doses of Shiga toxins and undergo apoptosis. J Infect Dis 180:2048–2052
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.26142-0
Loading
/content/journal/micro/10.1099/mic.0.26142-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed